AIOLOS BIO
Long Description: Aiolos Bio is a biotech company focused on developing therapies for respiratory diseases like asthma as well as other immune conditions. The company is initially focused on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma that only requires dosing every 6 months. Aiolos Bio was founded by an accomplished team with decades of drug development experience and leadership in the biotech industry.
AIOLOS BIO
Social Links:
Industry:
Biopharma Biotechnology Health Care
Founded:
2023-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.aiolosbio.com
Total Employee:
11+
Status:
Active
Total Funding:
245 M USD
Technology used in webpage:
British Server Location
Similar Organizations
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Georgiamune
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Harmony Biosciences
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Ocean Biomedical
Ocean Biomedical is a biotechnology company that accelerates new discoveries in the world of medicine.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Vera Therapeutics
Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential.
Current Advisors List
Current Employees Featured
Founder
Investors List
Forbion Capital Partners
Forbion Capital Partners investment in Series A - Aiolos Bio
Atlas Venture
Atlas Venture investment in Series A - Aiolos Bio
Sofinnova Investments
Sofinnova Investments investment in Series A - Aiolos Bio
RA Capital Management
RA Capital Management investment in Series A - Aiolos Bio
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series A - Aiolos Bio
Official Site Inspections
http://www.aiolosbio.com
- Host name: 213.11.111.34.bc.googleusercontent.com
- IP address: 34.111.11.213
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Aiolos Bio"
Aiolos Bio - Crunchbase Company Profile & Funding
Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.See details»
Aiolos Bio - LinkedIn
Today we are proud to announce a definitive merger agreement under which GSK will acquire Aiolos Bio for a total value of $1.4B. This deal will enable us to advance our mission of helping patients ...See details»
GSK enters agreement to acquire Aiolos Bio
Stock-exchange announcement For media and investors only Stock-exchange announcement 2 About Aiolos Bio Founded in 2023, Aiolos Bio is a San Francisco, USA and London, UK-based …See details»
GSK completes acquisition of Aiolos Bio
Feb 15, 2024 GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the …See details»
Aiolos Bio Company Profile 2024: Valuation, Investors ... - PitchBook
Aiolos Bio General Information Description. Operator of a clinical-stage biopharmaceutical company intended to focus on addressing the unmet treatment needs of patients with …See details»
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
Feb 15, 2024 GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions.See details»
GSK completes acquisition of Aiolos Bio – Company …
Issued: 15 February 2024, London UK GSK completes acquisition of Aiolos Bio GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio …See details»
GSK Boosts Respiratory Portfolio with $1.4 Billion ... - Investopedia
Jan 9, 2024 GSK PLC on Tuesday announced a deal to acquire asthma drugmaker Aiolos Bio Inc. for $1.4 billion. The deal includes a $1 billion upfront payment and $400 million in success …See details»
GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio
On Jan. 9, 2024, GSK and Aiolos Bio, a clinical-stage biopharmaceutical company specializing in the treatment of respiratory and inflammatory conditions, announced that they have entered …See details»
Aiolos Bio - Bain Capital Life Sciences
Founded in 2023, Aiolos Bio is a San Francisco, USA and London, UK-based clinical-stage, private, biopharmaceutical company dedicated to revolutionising the treatment landscape for …See details»
Aiolos Bio - Craft
Aiolos Bio $245 m in total funding,. See insights on Aiolos Bio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Forbion co-leads $245 million Series A financing of Aiolos
Oct 24, 2023 Our team has a long history of successful drug development in respiratory and immunological diseases – collectively amassing more than 30 FDA approvals – and seeks to …See details»
Aiolos Bio - Forbion
Www.aiolosbio.com Worked on by. Wouter Joustra, MSc General Partner. Read more Audrey Cacaly, MSc Principal. Audrey joined the Forbion team in 2021 Read more Alice Vickers, PhD …See details»
Data retrieved successfully. - Bain Capital
Oct 24, 2023 Bain Capital, LP is one of the world’s leading multi-asset alternative investment firms. With offices on four continents, our global team aligns our interests with those of our …See details»
Aiolos Bio Launches with $245 Million Series A ... - Business Wire
Oct 24, 2023 For more information, please visit www.aiolosbio.com. Contacts. Media: For Aiolos Bio: Scott Lessne Stanton [email protected] (646) 502-3569 Contacts.See details»
Aiolos Bio launches with $245M to advance severe asthma med
Oct 24, 2023 A consistent theme of 2023 has been that advanced assets attract seismic capital and a newly launched biotech adds more proof to the pile. Aiolos Bio is jetting out of stealth …See details»
GSK Enters Agreement to Acquire Aiolos Bio | Nasdaq
Jan 9, 2024 SAN FRANCISCO& LONDON---- GSK plc and Aiolos Bio, Inc. today announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage …See details»
GSK enters agreement to acquire Aiolos Bio
Jan 9, 2024 Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody.See details»
Aiolos Bio Launches with $245 Million Series A Investment to
Oct 24, 2023 SAN FRANCISCO & LONDON--(BUSINESS WIRE)-- Aiolos Bio, Inc. (“Aiolos” or “the Company”) today announced its launch as a clinical-stage biopharmaceutical company …See details»
Aiolos Bio raises $245M on prospect of better asthma drug
Oct 24, 2023 Aiolos Bio raises $245M on prospect of better asthma drug The Series A funding round ranks among the largest in the biotech industry this year, with investors including Atlas, …See details»